Morgan Stanley’s Verona Pharma VRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-1,575,904
| Closed | -$168M | – | 8479 |
|
|
2025
Q3 | $168M | Buy |
1,575,904
+1,393,574
| +764% | +$146M | 0.01% | 1029 |
|
|
2025
Q2 | $17.2M | Sell |
182,330
-1,441,797
| -89% | -$107M | ﹤0.01% | 2957 |
|
|
2025
Q1 | $103M | Buy |
1,624,127
+140,374
| +9% | +$8.4M | 0.01% | 1236 |
|
|
2024
Q4 | $68.9M | Buy |
1,483,753
+892,844
| +151% | +$33.5M | ﹤0.01% | 1546 |
|
|
2024
Q3 | $17M | Sell |
590,909
-273,122
| -32% | -$6.72M | ﹤0.01% | 2953 |
|
|
2024
Q2 | $12.5M | Buy |
864,031
+530,859
| +159% | +$7.75M | ﹤0.01% | 3146 |
|
|
2024
Q1 | $5.36M | Sell |
333,172
-148,024
| -31% | -$2.56M | ﹤0.01% | 3862 |
|
|
2023
Q4 | $9.57M | Buy |
481,196
+407,153
| +550% | +$6.01M | ﹤0.01% | 3385 |
|
|
2023
Q3 | $1.21M | Sell |
74,043
-6,885
| -9% | -$133K | ﹤0.01% | 4689 |
|
|
2023
Q2 | $1.71M | Sell |
80,928
-124,968
| -61% | -$2.67M | ﹤0.01% | 4517 |
|
|
2023
Q1 | $4.13M | Buy |
205,896
+34,778
| +20% | +$751K | ﹤0.01% | 3934 |
|
|
2022
Q4 | $4.47M | Buy |
171,118
+166,140
| +3,337% | +$2.21M | ﹤0.01% | 3847 |
|
|
2022
Q3 | $51K | Sell |
4,978
-4,807
| -49% | -$40.5K | ﹤0.01% | 6399 |
|
|
2022
Q2 | $41K | Buy |
9,785
+332
| +4% | +$1.42K | ﹤0.01% | 6696 |
|
|
2022
Q1 | $47K | Buy |
9,453
+2,185
| +30% | +$12.7K | ﹤0.01% | 6739 |
|
|
2021
Q4 | $48K | Sell |
7,268
-926
| -11% | -$4.73K | ﹤0.01% | 6835 |
|
|
2021
Q3 | $45K | Buy |
8,194
+4,520
| +123% | +$26.3K | ﹤0.01% | 6773 |
|
|
2021
Q2 | $24K | Buy |
3,674
+2,174
| +145% | +$15.1K | ﹤0.01% | 6948 |
|
|
2021
Q1 | $13K | Sell |
1,500
-128
| -8% | -$1.06K | ﹤0.01% | 6871 |
|
|
2020
Q4 | $12K | Buy |
1,628
+128
| +9% | +$865 | ﹤0.01% | 6593 |
|
|
2020
Q3 | $9K | Buy |
+1,500
| New | +$10.4K | ﹤0.01% | 6309 |
|
|
2019
Q2 | – | Sell |
-1
| Closed | – | – | 6753 |
|
|
2019
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 6711 |
|
|
2018
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 6744 |
|
|
2018
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 6812 |
|
|
2018
Q2 | $0 | Sell |
1
-200
| -100% | -$3.36K | ﹤0.01% | 6759 |
|
|
2018
Q1 | $4K | Buy |
201
+186
| +1,240% | +$2.69K | ﹤0.01% | 6431 |
|
|
2017
Q4 | $0 | Buy |
15
+1
| +7% | +$13 | ﹤0.01% | 6658 |
|
|
2017
Q3 | $0 | Buy |
+14
| New | +$185 | ﹤0.01% | 6623 |
|
Other funds holding VRNA
Morgan Stanley's VRNA Position: Q4 2025 in Review
Morgan Stanley sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 1,575,904 shares — an estimated $168M sold.
Morgan Stanley first reported a position in VRNA in Q3 2017 and held it in 28 quarters. The position peaked at $168M in Q3 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.
- Morgan Stanley reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
- Morgan Stanley sold 1,575,904 Verona Pharma shares in Q4 2025, an estimated $168M.
- Morgan Stanley first reported a position in Verona Pharma in Q3 2017 and held it in 28 quarters.
- Morgan Stanley's Verona Pharma position peaked at $168M in Q3 2025.
- 1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.
Based on Morgan Stanley's 13F filing for Q4 2025, filed 13 Feb 2026.